Vertex stock enters November FDA countdown after Q3 growth

Vertex Pharmaceuticals reported stronger third-quarter sales on November 2, with revenue growth across its cystic fibrosis portfolio and newer medicines. The company also raised its full-year outlook as it prepares for a November 30 FDA decision that could open a fifth commercial franchise.

Vertex stock traded at 491.70 euros on Lang & Schwarz at 14:41 CET on Tuesday, November 10, 2026.

Revenue growth broadens

In the quarter ended September 30, total revenue rose 12 percent year over year to 3.44 billion US dollars, according to Vertex's investor release. Revenue increased 10 percent in the United States to 2.17 billion US dollars and 16 percent outside the United States to 1.27 billion US dollars.

Cystic fibrosis remained the largest contributor, with quarterly product revenue of 3.27 billion US dollars. Trikafta and Kaftrio generated 2.44 billion US dollars, while Alyftrek contributed 705.8 million US dollars. The newer portfolio added further momentum: Casgevy revenue reached 99.2 million US dollars, Jour­navx revenue was 58.3 million US dollars and Palsonify generated 10.1 million US dollars after the Crinetics acquisition closed on September 1.

Vertex said the expansion of the commercial portfolio came with substantially higher costs. GAAP net income fell to 653.6 million US dollars from 1.08 billion US dollars a year earlier, mainly because of expenses tied to the Crinetics transaction. Non-GAAP net income was 1.21 billion US dollars, compared with 1.24 billion US dollars in the prior-year quarter. Non-GAAP diluted earnings per share were 4.76 US dollars, down from 4.80 US dollars.

Higher outlook and pipeline catalyst

Vertex raised its 2026 total revenue guidance to 13.15 billion to 13.25 billion US dollars, from 13.1 billion to 13.2 billion US dollars previously. The new range includes at least 500 million US dollars from Casgevy and Journavx combined and 40 million to 50 million US dollars from Palsonify.

The guidance change reflects the addition of Crinetics and continued growth in cystic fibrosis, rather than a broad reset of the underlying business assumptions. Vertex also expects higher combined GAAP research, development and selling expenses as it funds renal commercialization and integrates the acquisition. The company said the expense outlook includes about 500 million US dollars of compensation and transaction costs linked to Crinetics.

The most immediate pipeline event is the FDA's November 30 target action date for povetacicept in IgA nephropathy. The application is under priority review and is supported by interim Phase 3 RAINIER results. If approved, Vertex says povetacicept would become the first commercialized therapy in its planned nephrology franchise.

Management is also advancing povetacicept in primary membranous nephropathy and generalized myasthenia gravis. Enrollment in the Phase 2 dose-ranging study for generalized myasthenia gravis is complete, with results expected in the first half of 2027. These programs leave the stock exposed to both regulatory execution and the pace at which newer products offset the maturity of the cystic fibrosis franchise.

Broader market conditions remain relevant for US biotechnology shares; investors can follow the S&P 500 alongside company-specific catalysts.

For Vertex, the next major checkpoint is the FDA decision on November 30, followed by further clinical updates in 2027. More news and analyses on Vertex stock.